美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

全球基礎設施ETF-iShares

58.11

+0.97001.70%

盤後：58.110.00000.00%16:05 EDT

成交量：43.74萬

成交額：2,531.65萬

市值：65.08億

市盈率：- -

高：58.12

開：57.51

低：57.49

收：57.14

資料載入中...

總覽公司新聞公告

CESS Network 已通過政府區塊鏈 BMM 一級認證

信達生物IGF-1R抗體藥物獲批

信達生物(01801)：IGF-1R單抗信必敏獲批用於治療甲狀腺眼病

中國首個IGF-1R單抗：信達生物信必敏®獲批，填補甲狀腺眼病治療空白

信達生物(01801)：中國首個IGF-1R單抗信必敏®獲國家藥監局批准上市用於治療甲狀腺眼病

重磅！薩爾瓦多總統計劃開採價值3萬億美元的金礦

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/IGF/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IGF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IGF\",,,,,undefined,":{"symbol":"IGF","market":"US","secType":"STK","nameCN":"全球基礎設施ETF-iShares","latestPrice":58.11,"timestamp":1747339200000,"preClose":57.14,"halted":0,"volume":437401,"hourTrading":{"tag":"盘后","latestPrice":58.11,"preClose":58.11,"latestTime":"16:05 EDT","volume":248,"amount":14411.28,"timestamp":1747339516335},"delay":0,"floatShares":112000000,"shares":112000000,"eps":0,"marketStatus":"盤後交易","change":0.97,"latestTime":"05-15 18:41:10 EDT","open":57.51,"high":58.12,"low":57.49,"amount":25316475.038914,"amplitude":0.011026,"askPrice":59.99,"askSize":1,"bidPrice":49.86,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1747353600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":57.14,"sharesOutstanding":115800000,"nav":57.073507,"aum":6609112110.6,"bidAskSpread":0.000677,"preHourTrading":{"tag":"盘前","latestPrice":57.15,"preClose":57.14,"latestTime":"09:11 EDT","volume":2065,"amount":118034.745395,"timestamp":1747314682968},"postHourTrading":{"tag":"盘后","latestPrice":58.11,"preClose":58.11,"latestTime":"16:05 EDT","volume":248,"amount":14411.28,"timestamp":1747339516335},"volumeRatio":0.677129,"impliedVol":0.055,"impliedVolPercentile":0.352},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IGF\",,,,,undefined,":{"symbol":"IGF","floatShares":112000000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.677129,"shares":112000000,"dividePrice":1.67905,"high":58.12,"amplitude":0.011026,"preClose":57.14,"low":57.49,"week52Low":47.49,"pbRate":"--","week52High":58.12,"institutionHeld":0,"latestPrice":58.11,"committee":0.980198,"eps":0,"divideRate":0.028894,"volume":437401,"delay":0,"ttmEps":0,"open":57.51,"prevYearClose":52.27,"prevWeekClose":57.34,"prevMonthClose":56.39,"prevQuarterClose":54.67,"fiveDayClose":57.23,"twentyDayClose":54.84,"sixtyDayClose":54.29},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IGF\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531567337","title":"CESS Network 已通過政府區塊鏈 BMM 一級認證","url":"https://stock-news.laohu8.com/highlight/detail?id=2531567337","media":"BitPush","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531567337?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 22:21","pubTimestamp":1745936465,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bitpush.news//articles/7422692","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bit_push_live","symbols":["IGF"],"gpt_icon":0},{"id":"2519088875","title":"信達生物IGF-1R抗體藥物獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2519088875","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519088875?lang=zh_tw&edition=fundamental","pubTime":"2025-03-14 17:39","pubTimestamp":1741945169,"startTime":"0","endTime":"0","summary":"3月14日，信达生物（01801）发布公告，宣布其研发的IGF-1R抗体信必敏?（替妥尤单抗N01注射液）已获得中国国家药品监督管理局的批准，用于治疗甲状腺眼病。这是中国首个获批的IGF-1R抗体药物，也是全球第二款，标志着该公司在重大疾病治疗领域的又一里程碑。该药物的安全性良好，能够显著改善患者的炎症和生活质量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503143346198629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2328871848.SGD","LU2488822045.USD","IGF","BK1583","BK1589","LU1969619763.USD","01801","BK1161"],"gpt_icon":0},{"id":"2519821970","title":"信達生物(01801)：IGF-1R單抗信必敏獲批用於治療甲狀腺眼病","url":"https://stock-news.laohu8.com/highlight/detail?id=2519821970","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519821970?lang=zh_tw&edition=fundamental","pubTime":"2025-03-14 16:36","pubTimestamp":1741941392,"startTime":"0","endTime":"0","summary":"金吾财讯 | 信达生物(01801)宣布，重组抗胰岛素样生长因子1受体（“IGF-1R”）抗体信必敏（替妥尤单抗N01注射液）的新药上市申请（“NDA”）获中国国家药品监督管理局（“NMPA”）批准上市，用于治疗甲状腺眼病(Thyroid Eye Disease,TED)。信必敏是中国首个、全球第二款获批的IGF-1R抗体药物，也是中国甲状腺眼病治疗领域70年来的首款新药，将重塑甲状腺眼病的治疗标准。甲状腺眼病是与甲状腺疾病密切相关的一种器官特异自身免疫性疾病，位居成人眼眶疾病发病率首位，在40-60岁年龄段尤其高发。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/NzJkY2Y1NGFiZmJjZmI1MTMzYzFhNzg2YjE4NjgwNzc5NTAwMDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NzJkY2Y1NGFiZmJjZmI1MTMzYzFhNzg2YjE4NjgwNzc5NTAwMDI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1955101","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","01801","LU2328871848.SGD","BK1161","BK1583","IGF","LU2488822045.USD","LU1969619763.USD"],"gpt_icon":0},{"id":"2519356777","title":"中國首個IGF-1R單抗：信達生物信必敏®獲批，填補甲狀腺眼病治療空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2519356777","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519356777?lang=zh_tw&edition=fundamental","pubTime":"2025-03-14 16:35","pubTimestamp":1741941300,"startTime":"0","endTime":"0","summary":"信必敏是中国首个、全球第二款获批的IGF-1R抗体药物，也是中国甲状腺眼病治疗领域70年来的首款新药，将重塑甲状腺眼病的治疗标准。信必敏作为中国首个获批的IGF-1R抗体，疗效优异，安全性良好，为甲状腺眼病患者带来了全新可及的治疗选择，具有重要的临床及社会价值。2025年3月，信必敏获中国国家药品监督管理局批准用于治疗甲状腺眼病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4641219_ZH41219_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1589","BK4139","01801","BK1161","LU2328871848.SGD","LU1969619763.USD","BK1583","LU2488822045.USD","IGF","IVBIY"],"gpt_icon":0},{"id":"2519982929","title":"信達生物(01801)：中國首個IGF-1R單抗信必敏®獲國家藥監局批准上市用於治療甲狀腺眼病","url":"https://stock-news.laohu8.com/highlight/detail?id=2519982929","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519982929?lang=zh_tw&edition=fundamental","pubTime":"2025-03-14 16:34","pubTimestamp":1741941253,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布公告，重组抗胰岛素样生长因子1受体抗体信必敏 的新药上市申请获中国国家药品监督管理局批准上市，用于治疗甲状腺眼病。信必敏是中国首个、全球第二款获批的IGF-1R抗体药物，也是中国甲状腺眼病治疗领域70年来的首款新药，将重塑甲状腺眼病的治疗标准。信必敏作为中国首个获批的IGF-1R抗体，疗效优异，安全性良好，为甲状腺眼病患者带来了全新可及的治疗选择，具有重要的临床及社会价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1261945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1969619763.USD","LU2328871848.SGD","01801","IGF","BK1589","BK1583","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2490262885","title":"重磅！薩爾瓦多總統計劃開採價值3萬億美元的金礦","url":"https://stock-news.laohu8.com/highlight/detail?id=2490262885","media":"金十数据","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490262885?lang=zh_tw&edition=fundamental","pubTime":"2024-12-11 14:38","pubTimestamp":1733899081,"startTime":"0","endTime":"0","summary":"萨尔瓦多总统宣称，“我们可能拥有世界上每平方公里最大的金矿。上帝在我们脚下放置了巨大的宝藏，采矿禁令是荒谬的。”","market":"hk","thumbnail":"https://img.jin10.com/gallary/6c56d253-75d4-430c-878f-564a07904fa0.png/lite","type":0,"news_type":0,"thumbnails":["https://img.jin10.com/gallary/6c56d253-75d4-430c-878f-564a07904fa0.png/lite"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://xnews.jin10.com/webapp/details.html?id=155743&type=news&data_type=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"xnew_highlight","symbols":["IGF"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IGF\",params:#limit:5,,,undefined,":[{"date":"2024-12-17","symbol":"IGF","amount":0.84896,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"全球基础设施ETF-iShares","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IGF","amount":0.83009,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"全球基础设施ETF-iShares","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"},{"date":"2023-12-20","symbol":"IGF","amount":0.906875,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares S&P Global Infrastructur","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IGF","amount":0.675429,"announcedDate":"2023-06-06","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares S&P Global Infrastructur","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"},{"market":"US","date":"2022-12-13","symbol":"IGF","amount":0.5179,"defaultRemindTime":1670941800000,"name":"iShares S&P Global Infrastructur","recordDate":"2022-12-19","payableDate":"2022-12-14","currency":"USD","type":"dividend","dateTimestamp":1670907600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IGF\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-24","recordDate":"2015-06-26","paymentDate":"2015-06-30","value":0.529444,"currency":"USD"},{"executeDate":"2015-12-21","recordDate":"2015-12-23","paymentDate":"2015-12-28","value":0.637463,"currency":"USD"},{"executeDate":"2016-06-21","recordDate":"2016-06-23","paymentDate":"2016-06-27","value":0.631518,"currency":"USD"},{"executeDate":"2016-12-22","recordDate":"2016-12-27","paymentDate":"2016-12-29","value":0.533733,"currency":"USD"},{"executeDate":"2017-06-20","recordDate":"2017-06-22","paymentDate":"2017-06-26","value":0.735844,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IGF\",market:\"US\",delay:false,,,undefined,":{}}}